Oxytocin: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข5 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Store injectable oxytocin at 2-8C (refrigerator). Protect from light. Do not freeze. Intranasal formulations: store at room temperature (15-25C) or as specified by manufacturer. Discard per manufacturer expiration date. Multi-dose injectable vials should be discarded 28 days after opening.
Protocol Quick-Reference
Social bonding, anxiety reduction, and investigational use in autism/PTSD research
Dosing
Amount
24 IU intranasal (6 sprays of 4 IU each, 3 per nostril)
Frequency
Once or twice daily for research protocols
Duration
4-24 weeks in clinical research; single dose for acute social cognition studies
Administration
Route
IntranasalSchedule
Once or twice daily for research protocols
Timing
30-45 minutes before behavioral assessments or therapy sessions; morning or early afternoon preferred
Cycle
Duration
4-24 weeks in clinical research; single dose for acute social cognition studies
Repeatable
Single cycle
Preparation & Storage
โ Ready-to-use โ no reconstitution required
Storage: Store injectable oxytocin at 2-8C (refrigerator). Protect from light. Do not freeze. Intranasal formulations: store at room temperature (15-25C) or as specified by manufacturer. Discard per manufacturer expiration date. Multi-dose injectable vials should be discarded 28 days after opening.
โ๏ธ Suggested Bloodwork (6 tests)
Comprehensive metabolic panel (CMP)
When: Baseline
Why: Baseline kidney/liver function and electrolytes (hyponatremia risk)
Serum sodium
When: Baseline
Why: Oxytocin has antidiuretic properties; baseline sodium critical
CBC
When: Baseline
Why: General health baseline
Hormone panel (estradiol, progesterone, testosterone)
When: Baseline
Why: Oxytocin interacts with sex hormone pathways
Serum sodium
When: 2-4 weeks
Why: Monitor for hyponatremia, especially with higher doses or chronic use
CMP
When: 4-8 weeks
Why: Monitor electrolyte balance during ongoing use
๐ก Key Considerations
- โContraindication: Avoid during pregnancy (except obstetric use under medical supervision) due to uterotonic effects; caution with cardiovascular disease or water/electrolyte imbalances
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Labor induction (FDA-approved) | 0.5-2 mU/min initial, increase by 1-2 mU/min every 30-60 min | Continuous IV infusion | Until adequate labor established or delivery | Low-dose protocol. Maximum dose typically 20-40 mU/min. Requires continuous electronic fetal monitoring and trained obstetric personnel. Controlled infusion pump mandatory. |
| Labor augmentation (FDA-approved) | 0.5-2 mU/min initial, titrate to contraction pattern | Continuous IV infusion | Until adequate labor pattern achieved | Used when spontaneous labor is inadequate. Lower doses often sufficient compared to induction. Same monitoring requirements as induction. |
| Postpartum hemorrhage prevention (FDA-approved) | 10-40 units in 1000 mL IV fluid at adjusted rate | Single administration post-delivery | 1-4 hours post-delivery | WHO recommends 10 IU IM or IV for active management of third stage of labor. Alternative: 10 IU IM immediately after placental delivery. |
| Intranasal (autism/social cognition research) | 24-40 IU per dose | Once or twice daily | 4-24 weeks (varies by study) | Standard research dose in adults. NEJM ASD trial used age-adjusted doses (8-40 IU). Administered via nasal spray device. Effects may be context-dependent and individually variable. |
| Intranasal (PTSD/anxiety research) | 20-40 IU per dose | Single dose before therapy sessions or twice daily | 2-8 weeks (varies by study) | Administered 45-60 minutes before psychotherapy sessions in augmentation trials. Also studied as standalone twice-daily treatment for anxiety disorders. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Pharmaceutical-grade oxytocin (Pitocin/Syntocinon) is provided as a ready-to-use sterile solution for injection (10 units/mL). For IV infusion, dilute in normal saline or lactated Ringer's solution. For intranasal research use, oxytocin is provided in metered-dose nasal spray devices (typically 4 IU per spray). No reconstitution required for commercial formulations.
Recommended Injection Sites
- โIntravenous (continuous infusion via controlled pump, for obstetric use)
- โIntramuscular (deltoid or gluteal, for PPH prevention)
- โIntranasal (nasal spray, for research applications)
๐งStorage Requirements
Store injectable oxytocin at 2-8C (refrigerator). Protect from light. Do not freeze. Intranasal formulations: store at room temperature (15-25C) or as specified by manufacturer. Discard per manufacturer expiration date. Multi-dose injectable vials should be discarded 28 days after opening.
Community Dosing Protocols
Compare these clinical doses with what 70+ community members report using.
Based on 70+ community reports
View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Dosing Information#
FDA-Approved Dosing (Obstetric Use)#
Labor Induction#
Oxytocin infusion for labor induction follows carefully controlled dose-escalation protocols. Two main approaches are used:
Low-Dose Protocol (Most Common):
| Time | Dose | Action |
|---|---|---|
| Start | 0.5-2 mU/min | Initiate IV infusion |
| Every 30-60 min | Increase by 1-2 mU/min | Titrate to contractions |
| Target | 3-5 contractions per 10 min | Maintain effective dose |
| Maximum | 20-40 mU/min | Do not exceed |
High-Dose Protocol:
| Time | Dose | Action |
|---|---|---|
| Start | 6 mU/min | Initiate IV infusion |
| Every 15-40 min | Increase by 6 mU/min | Aggressive titration |
| Target | Regular contractions | Maintain effective dose |
| Maximum | 42 mU/min | Do not exceed |
High-dose protocols may achieve active labor more quickly but carry increased risk of tachysystole and uterine hyperstimulation. The choice of protocol depends on institutional practice and clinical circumstances.
Labor Augmentation#
For augmentation of inadequate spontaneous labor, the starting dose is typically 0.5-2 mU/min with increments of 1-2 mU/min every 30-60 minutes. Lower maximum doses are often sufficient compared to induction, as the uterus is already primed for labor.
Postpartum Hemorrhage Prevention#
The WHO recommends oxytocin as the first-line uterotonic for active management of the third stage of labor:
- Standard dose: 10 IU intramuscular immediately after delivery of the placenta
- Alternative: 10-40 units added to 1000 mL IV fluid and infused at a rate to control uterine atony
- For treatment of established PPH: Higher doses may be needed, often in combination with other uterotonics (ergometrine, misoprostol, carbetocin)
Intranasal Dosing (Research)#
Autism Spectrum Disorder Trials#
The NEJM Phase III trial used age-adjusted intranasal dosing:
- Children aged 3-5 years: 8 IU per dose
- Children aged 6-11 years: 16 IU per dose
- Adolescents aged 12-17 years: 24-40 IU per dose
- Frequency: Twice daily
- Duration: 24 weeks
PTSD and Anxiety Research#
- Pre-therapy augmentation: 20-40 IU administered 45-60 minutes before psychotherapy sessions
- Daily treatment: 24 IU twice daily in some protocols
- Duration: Typically 2-8 weeks in published trials
Social Cognition Studies#
Most acute social cognition studies use a single dose of 20-40 IU (typically 24 IU) administered 30-45 minutes before behavioral testing. The 24 IU dose (6 sprays of 4 IU each, 3 per nostril) has become the most common standard in adult research.
Administration#
Intravenous (Obstetric)#
- Prepare oxytocin solution: typically 10-30 units in 1000 mL normal saline or lactated Ringer's
- Connect to a controlled infusion pump (gravity drip is NOT acceptable)
- Use a secondary (piggyback) line connected to the primary IV line close to the insertion site
- Start at the prescribed initial rate
- Titrate according to protocol based on contraction pattern and fetal heart rate
- Initiate continuous electronic fetal monitoring before starting infusion
- Document all dose changes, contraction patterns, and fetal heart rate assessments
Intramuscular (PPH Prevention)#
- Draw up 10 IU (1 mL) of oxytocin into a syringe
- Administer by deep intramuscular injection into the deltoid or gluteal muscle
- Timing: immediately after delivery of the placenta (within 1 minute)
Intranasal (Research)#
- Have the participant clear their nostrils
- Shake the nasal spray device gently
- Insert the spray nozzle into one nostril
- Administer one spray while the participant inhales gently
- Alternate nostrils for subsequent sprays
- Typical protocol: 3 sprays per nostril (6 total) for a 24 IU dose (4 IU per spray)
- Wait 30-45 minutes before conducting behavioral assessments
Storage Guidelines#
Injectable Formulation (Pitocin)#
- Storage: 2-8 degrees Celsius (refrigerator)
- Protection: Keep away from light
- Do not freeze
- Room temperature: Stable for limited periods (consult manufacturer guidance)
- Multi-dose vials: Discard 28 days after opening
Intranasal Spray#
- Storage: Room temperature (15-25 degrees Celsius) or as specified
- Protection: Keep away from excessive heat and light
- Stability: Use within manufacturer's expiration date
- In-use: Replace nasal spray tip regularly to prevent contamination
Dose-Response Considerations#
The dose-response relationship for oxytocin varies substantially by route and indication:
- Obstetric: Clear dose-response for uterine contractions; doses above threshold do not increase efficacy but increase adverse event risk
- Intranasal behavioral: The dose-response relationship for CNS effects is not well established. The 2025 meta-analysis suggested that higher intranasal doses may be more effective for ASD symptoms, but this finding requires confirmation
- Individual variability: Significant inter-individual variation in response to intranasal oxytocin has been documented, likely related to genetic differences in OXTR expression and baseline oxytocin levels
Evidence Gaps#
- Optimal intranasal dose for psychiatric applications not established despite decades of research
- Dose-response relationship for CNS effects after intranasal delivery poorly characterized
- Whether chronic dosing leads to tolerance or tachyphylaxis is unknown
- Optimal timing of intranasal administration relative to behavioral outcomes not determined
- Age-specific and sex-specific dosing guidelines for intranasal use not available
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Oxytocin
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.